Roles of MiR-17-92 Cluster MicroRNAs in K-Ras-Induced Pancreatic Tumorigenesis
Roles of MiR-17-92 Cluster MicroRNAs in K-Ras-Induced Pancreatic Tumorigenesis
批准号:
8634067
负责人:
Brian Joseph Quattrochi
金额:
$2.92万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-04-01 至 2016-03-31
关键词:
AddressAdenocarcinoma CellAffectAge-MonthsAlgorithmsAnimalsApoptoticAutomobile DrivingBiologyCancer EtiologyCarcinomaCell LineCell ProliferationCell SurvivalCellsCessation of lifeDataDevelopmentDiagnosisDiseaseDuctal Epithelial CellEarly DiagnosisEpithelial CellsFoundationsGenesHistologicIn VitroKRAS2 geneKnowledgeLesionLightLuciferasesMEKsMalignant neoplasm of pancreasMeasuresMediatingMessenger RNAMicroRNAsMolecularMutationOncogenicPancreasPancreatic Ductal AdenocarcinomaPathway interactionsPatientsPhenotypePlayPropertyProteinsProto-Oncogene Proteins c-aktRegulationResearchRoleSignal PathwaySignal TransductionStagingStimulusSurvival RateSystemic diseaseTP53 geneTherapeuticTimeTissuesTumor Suppressor GenesUnited StatesUntranslated RegionsWestern BlottingWorkbasecancer initiationeffective therapyimprovedin vivoluminescencemouse modelnovel therapeutic interventionpancreatic tumorigenesisresearch studystatisticstumortumor progressiontumorigenesistumorigenic
中文摘要
描述(由申请人提供):胰腺导管腺癌(PDAC)是美国癌症相关死亡的第四大原因,5年生存率低于5%,诊断后中位生存期为6个月。这些统计数字反映了缺乏有效的早期发现和缺乏对系统性疾病的有效治疗。在开发更有针对性和有效的治疗方法之前,需要对PDAC启动和进展的基础生物学有更多的了解。本研究将探索PDAC(mutationally activated KrasG 12 D)驱动突变与miR-17~92 microRNA簇之间的潜在关系,特别是探讨胰腺内Kras增殖、促生存和致瘤表型对miR-17~92的需求以及这种关系背后的分子机制。为了确定KrasG 12 D诱导的细胞表型是否需要miR-17~92 miRNA,将分离原代导管上皮细胞(PDEC),并确定在凋亡刺激物存在下miR-17~92缺失对KrasG 12 D诱导的增殖和存活的影响。miRNA簇的组分将外源表达以评估特异性miRNA对这些表型的潜在拯救。将在内源性表达KrasG 12 D并在胰腺中特异性缺失miR-17 ~ 92簇的动物中评估miR-17 ~ 92簇的缺失对体内PDAC前体病变形成的影响。在4、8和12月龄时处死动物,并检查胰腺组织切片中前驱病变的存在、数量和等级。使用另外并入TP 53肿瘤抑制基因的杂合缺失的小鼠模型,将确定miR-17~92缺失对PDAC发生和进展的影响。这些研究是具体目标1的重点。本研究还将探讨miR-17~92簇与激活的Kras相互作用的机制。通过使用多靶点预测算法和来自表达KrasG 12 D的PDEC的信使RNA微阵列谱的数据,将鉴定PDEC中表达的miR-17~92簇的可能靶点。将通过Western印迹评估miR-17~92野生型和无效PDEC中的表达水平,并通过将靶3 'UTR融合至荧光素酶并测量具有和不具有miRNA簇的细胞中的发光来确认miRNA介导的抑制。将在簇无效PDEC中测量Kras的下游途径活性,以确定17~92是否通过调节特异性下游效应物途径来调节KrasG 12 D诱导的表型。这些研究是具体目标2的重点。总之,本申请中提出的研究将揭示miR-17~92 miRNA簇在胰腺癌发生和发展中的作用,可能为开发新的治疗方法奠定基础。
英文摘要
DESCRIPTION (provided by applicant): Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in the United States, with a five-year survival rate of less than 5%, and a median survival after diagnosis of 6 months. These statistics reflect the lack of effective early detection and the absence of effective treatments for systemic disease. Greater knowledge of the underlying biology of PDAC initiation and progression is required before more targeted and effective therapies can be developed. The proposed work will explore the potential relationship between the driving mutation of PDAC (mutationally activated KrasG12D) and the miR-17~92 cluster of microRNAs, specifically addressing the requirement for miR-17~92 in Kras' proliferative, pro-survival and tumorigenic phenotypes within the pancreas and the molecular mechanism behind this relationship. To determine whether miR-17~92 miRNAs are required for KrasG12D-induced cellular phenotypes, primary ductal epithelial cells (PDECs) will be isolated and the effect of miR-17~92 deletion on KrasG12D-induced proliferation and survival in the presence of apoptotic stimuli will be determined. Components of the miRNA cluster will be expressed exogenously to assess potential rescue of these phenotypes by specific miRNAs. The effect of deletion of the miR-17~92 cluster on PDAC precursor lesion formation in vivo will be assessed in animals that endogenously express KrasG12D and have deleted the miR-17~92 cluster specifically in the pancreas. Animals will be sacrificed at 4, 8, and 12 months of age and histologic sections of the pancreas examined for the presence, quantity and grade of precursor lesions. Using a mouse model that additionally incorporates heterozygous deletion of the TP53 tumor suppressor gene, the impact of miR-17~92 deletion on PDAC development and progression will be ascertained. These studies are the focus of Specific Aim 1. This study will also identify the mechanism of interaction between the miR-17~92 cluster and activated Kras. Through the use of multiple target prediction algorithms and data from a messenger RNA microarray profile of PDECs expressing KrasG12D, probable targets of the miR-17~92 cluster that are expressed in PDECs will be identified. Expression levels will be evaluated in miR-17~92 wild type and null PDECs by Western blot, and miRNA-mediated suppression will be confirmed by fusing target 3'UTRs to luciferase and measuring luminescence in cells with and without the miRNA cluster. Downstream pathway activity of Kras will be measured in cluster-null PDECs to address whether 17~92 modulates KrasG12D-induced phenotypes through the regulation of specific downstream effector pathways. These studies are the focus of Specific Aim 2. Together, the studies proposed in this application will shed light on the role of the miR-17~92 miRNA cluster in pancreatic cancer initiation and progression, potentially laying the foundation for the development of novel therapeutic approaches.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Roles of MiR-17-92 Cluster MicroRNAs in K-Ras-Induced Pancreatic Tumorigenesis
-
批准号:8316836
-
项目类别:
-
资助金额:$2.87万
-
财政年份:2012
-
负责人:Brian Joseph Quattrochi
-
依托单位:
Roles of MiR-17-92 Cluster MicroRNAs in K-Ras-Induced Pancreatic Tumorigenesis
-
批准号:8465753
-
项目类别:
-
资助金额:$2.87万
-
财政年份:2012
-
负责人:Brian Joseph Quattrochi
-
依托单位:
海外基金